Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess the Effect and Tolerability of Limosilactobacillus Reuteri DSM 17648 Supplement in Healthy Adults Reporting Upper Gastrointestinal Discomfort

NCT07163637 is registered in ClinicalTrials.gov with Novozymes A/S as lead sponsor.

NCT NCT07163637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07163637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess the Effect and Tolerability of Limosilactobacillus Reuteri DSM 17648 Supplement in Healthy Adults Reporting Upper Gastrointestinal Discomfort
Lead sponsor
Novozymes A/S
Phase
Not applicable
Overall status
Completed
Start date
September 8, 2025
Completion date
May 27, 2026
Enrollment
324 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, upper gastrointestinal discomfort